Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (541-550 of 962) with videos related to

Pageof 97
Sort By:
Lancet (London, England)|September 7, 2012
Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trialEdoardo Camenzind, William Wijns, Laura Mauri, et al.
JACC. Cardiovascular Interventions|January 25, 2015
Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography)Peter Clemmensen, Sebastian Wiberg, Arnoud Van't Hof, et al.
Diabetes Care|February 6, 2025
Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized TrialGregory G Schwartz, Michael Szarek, J Wouter Jukema, et al.
Circulation|May 2, 2007
Clinical end points in coronary stent trials: a case for standardized definitionsDonald E Cutlip, Stephan Windecker, Roxana Mehran, et al.
Journal of the American Heart Association|May 16, 2020
Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 TrialRemo H M Furtado, Ramkumar V Venkateswaran, Jose C Nicolau, et al.
The American Journal of Cardiology|September 22, 2009
Impact of systemic hypertension on the diagnostic performance of B-type natriuretic peptide in patients with acute dyspneaAndreas S Pahle, Daniel Sørli, Torbjørn Omland, et al.
JAMA Cardiology|December 1, 2016
Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION TrialsMuthiah Vaduganathan, Robert A Harrington, Gregg W Stone, et al.
The American Journal of Cardiology|April 11, 2003
Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study)Gilles Montalescot, Claire Bal-dit-Sollier, Daniela Chibedi, et al.
Circulation. Cardiovascular Quality and Outcomes|January 5, 2019
Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding RiskUsman Baber, Daniel E Leisman, David J Cohen, et al.
Clinical Chemistry|November 5, 2016
Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart DiseaseEmil Hagström, Claes Held, Ralph A H Stewart, et al.
Pageof 97

Showing results (541-550 of 962) with videos related to

Sort By:
Pageof 97
Lancet (London, England)|September 7, 2012
Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trialEdoardo Camenzind, William Wijns, Laura Mauri, et al.
JACC. Cardiovascular Interventions|January 25, 2015
Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography)Peter Clemmensen, Sebastian Wiberg, Arnoud Van't Hof, et al.
Diabetes Care|February 6, 2025
Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized TrialGregory G Schwartz, Michael Szarek, J Wouter Jukema, et al.
Circulation|May 2, 2007
Clinical end points in coronary stent trials: a case for standardized definitionsDonald E Cutlip, Stephan Windecker, Roxana Mehran, et al.
Journal of the American Heart Association|May 16, 2020
Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 TrialRemo H M Furtado, Ramkumar V Venkateswaran, Jose C Nicolau, et al.
The American Journal of Cardiology|September 22, 2009
Impact of systemic hypertension on the diagnostic performance of B-type natriuretic peptide in patients with acute dyspneaAndreas S Pahle, Daniel Sørli, Torbjørn Omland, et al.
JAMA Cardiology|December 1, 2016
Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION TrialsMuthiah Vaduganathan, Robert A Harrington, Gregg W Stone, et al.
The American Journal of Cardiology|April 11, 2003
Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study)Gilles Montalescot, Claire Bal-dit-Sollier, Daniela Chibedi, et al.
Circulation. Cardiovascular Quality and Outcomes|January 5, 2019
Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding RiskUsman Baber, Daniel E Leisman, David J Cohen, et al.
Clinical Chemistry|November 5, 2016
Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart DiseaseEmil Hagström, Claes Held, Ralph A H Stewart, et al.
Pageof 97